Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Biosecurity practices on foie gras duck farms, Southwest France.

Delpont M, Blondel V, Robertet L, Duret H, Guerin JL, Vaillancourt JP, Paul MC.

Prev Vet Med. 2018 Oct 1;158:78-88. doi: 10.1016/j.prevetmed.2018.07.012. Epub 2018 Jul 26.

PMID:
30220399
2.

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Paget C, Chow MT, Gherardin NA, Beavis PA, Uldrich AP, Duret H, Hassane M, Souza-Fonseca-Guimaraes F, Mogilenko DA, Staumont-Sallé D, Escalante NK, Hill GR, Neeson P, Ritchie DS, Dombrowicz D, Mallevaey T, Trottein F, Belz GT, Godfrey DI, Smyth MJ.

Immunol Cell Biol. 2015 Feb;93(2):198-212. doi: 10.1038/icb.2014.94. Epub 2014 Nov 11.

3.

Type I NKT-cell-mediated TNF-α is a positive regulator of NLRP3 inflammasome priming.

Chow MT, Duret H, Andrews DM, Faveeuw C, Möller A, Smyth MJ, Paget C.

Eur J Immunol. 2014 Jul;44(7):2111-20. doi: 10.1002/eji.201344329. Epub 2014 Apr 29.

4.

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Cancer Res. 2014 Jan 15;74(2):436-45. doi: 10.1158/0008-5472.CAN-13-1265. Epub 2013 Dec 3.

5.

TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lépinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londoño-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E.

Nat Cell Biol. 2013 Jul;15(7):818-28. doi: 10.1038/ncb2774. Epub 2013 Jun 23.

PMID:
23792691
6.

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G.

Immunity. 2013 Apr 18;38(4):729-41. doi: 10.1016/j.immuni.2013.03.003. Epub 2013 Apr 4.

7.

Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.

Paget C, Duret H, Ngiow SF, Kansara M, Thomas DM, Smyth MJ.

Oncoimmunology. 2012 Nov 1;1(8):1313-1322.

8.

Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.

Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ.

Immunol Cell Biol. 2013 Jan;91(1):105-14. doi: 10.1038/icb.2012.58. Epub 2012 Oct 23.

PMID:
23090488
9.

NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases.

Chow MT, Sceneay J, Paget C, Wong CS, Duret H, Tschopp J, Möller A, Smyth MJ.

Cancer Res. 2012 Nov 15;72(22):5721-32. doi: 10.1158/0008-5472.CAN-12-0509. Epub 2012 Sep 17.

10.

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, Bots M, Zuber J, Lowe SW, Johnstone RW, Smyth MJ.

Blood. 2012 Oct 11;120(15):3019-29. doi: 10.1182/blood-2012-04-426643. Epub 2012 Aug 28.

11.

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.

Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ.

Cancer Res. 2012 Aug 15;72(16):3987-96. doi: 10.1158/0008-5472.CAN-12-1337. Epub 2012 Aug 6.

12.

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, Haynes NM.

Cancer Res. 2012 Jul 1;72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210. Epub 2012 May 8.

13.

Role of γδ T cells in α-galactosylceramide-mediated immunity.

Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ.

J Immunol. 2012 Apr 15;188(8):3928-39. doi: 10.4049/jimmunol.1103582. Epub 2012 Mar 12.

14.

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.

Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ.

Cancer Res. 2011 Jul 15;71(14):4809-20. doi: 10.1158/0008-5472.CAN-11-0753. Epub 2011 Jun 6.

15.

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7. doi: 10.1073/pnas.1016569108. Epub 2011 Apr 11.

16.

CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.

Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ.

Cancer Res. 2011 Apr 15;71(8):2892-900. doi: 10.1158/0008-5472.CAN-10-4246. Epub 2011 Feb 3.

17.

Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.

Teng MW, von Scheidt B, Duret H, Towne JE, Smyth MJ.

Cancer Res. 2011 Mar 15;71(6):2077-86. doi: 10.1158/0008-5472.CAN-10-3994. Epub 2011 Jan 31.

Supplemental Content

Support Center